Sarepta Therapeutic’s Positive Rating Reaffirmed at Needham & Company (SRPT)
Sarepta Therapeutic (NASDAQ:SRPT)‘s stock had its “positive” rating reiterated by equities researchers at Needham & Company in a research report issued on Monday, American Banking and Market News reports.
Other equities research analysts have also recently issued reports about the stock. Analysts at Piper Jaffray Cos. upgraded shares of Sarepta Therapeutic (NASDAQ:SRPT) from a “neutral” rating to an “overweight” rating in a research note to investors on Friday. Separately, analysts at Deutsche Bank upgraded shares of Sarepta Therapeutic (NASDAQ:SRPT) from a “hold” rating to a “buy” rating in a research note to investors on Friday. They now have a $71.00 price target on the stock, up previously from $45.00. Finally, analysts at Stifel Nicolaus initiated coverage on shares of Sarepta Therapeutic (NASDAQ:SRPT) in a research note to investors on Thursday, September 5th. They set a “buy” rating and a $51.00 price target on the stock.
Six research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $52.43.
Shares of Sarepta Therapeutic (NASDAQ:SRPT) opened at 43.30 on Monday. Sarepta Therapeutic has a 52-week low of $13.99 and a 52-week high of $47.35. The stock has a 50-day moving average of $35.37 and a 200-day moving average of $36.14. The company’s market cap is $1.452 billion. Sarepta Therapeutic also saw some unusual options trading activity on Friday. Investors bought 22,119 call options on the company. This is an increase of approximately 1,009% compared to the average daily volume of 1,995 call options.
Sarepta Therapeutic (NASDAQ:SRPT) last announced its earnings results on Thursday, August 8th. The company reported ($0.46) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.67) by $0.21. The company had revenue of $3.00 million for the quarter, compared to the consensus estimate of $5.08 million. The company’s quarterly revenue was down 73.2% on a year-over-year basis. Analysts expect that Sarepta Therapeutic will post $-3.24 EPS for the current fiscal year.
In other Sarepta Therapeutic news, Director M Kathleen Behrens bought 6,500 shares of the stock on the open market in a transaction that occurred on Monday, September 16th. The stock was purchased at an average price of $37.04 per share, with a total value of $240,760.00. Following the completion of the transaction, the director now directly owns 44,166 shares in the company, valued at approximately $1,635,909. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Sarepta Therapeutics Inc, formerly AVI BioPharma, Inc, is a biopharmaceutical company focused on the discovery and development of ribonucleic acid (NASDAQ:SRPT)-based therapeutics for the treatment of both rare and infectious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.